AstraZeneca has decided to abandon two phase 3 trials of its drug to reduce high levels of potassium in the blood (hyperkalaemia) – Lokelma – in patients with kidney disease. The STABILIZE-CKD ...

NICE says that Lokelma can be used for non-dialysed patients with CKD or heart failure who have persistent hyperkalaemia with a potassium level of 6.0 mmol/litre or more that is preventing them ...